Endogenous / BiologyEndogenousHuman-supportedUpdated 2026-04-22

Peptide reference file

Somatostatin

Trending #11 in Endogenous8.4k searches/moProven

Somatostatin is an endogenous inhibitory peptide hormone that signals through somatostatin receptor subtypes across endocrine and neuroendocrine systems.

Current readout: human-supported evidence, endogenous status, endogenous approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 16129706 | 45898 PubMed results | 356 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

Somatostatin is mostly discussed because it is the biology behind clinically important analogs like octreotide.

The public claim is straightforward: People connect somatostatin with blocking or slowing hormone release. The native hormone and approved analog drugs should be explained separately.

In plain language, somatostatin is an inhibitory peptide hormone that signals through somatostatin receptors.

Human-supportedEndogenous
SSTR receptorsHormone inhibitionNeuroendocrine

Aliases: Growth hormone-inhibiting hormone, SST

SpecimenSomatostatin specimen
CCCCCHHHHHHHNOS
Formula
C76H104N18O19S2
Mass
1637.9
Evidence
Human-supported
Elements
5

Most commonly discussed in relation to SSTR receptors, Hormone inhibition, Neuroendocrine.

What Somatostatin is

Somatostatin is an endogenous inhibitory peptide hormone that signals through somatostatin receptor subtypes across endocrine and neuroendocrine systems.

Somatostatin is grouped under Endogenous / Biology on PeptideFactCheck because it is the biology behind clinically important analogs like octreotide.

The useful starting point is to separate the molecule itself from the internet story around it. It is the native biology behind drugs like octreotide.

Why people keep looking it up

People connect somatostatin with blocking or slowing hormone release.

Somatostatin is an inhibitory peptide hormone that signals through somatostatin receptors.

Somatostatin tends to stay in the conversation because it touches a familiar public theme: sstr receptors, hormone inhibition, and neuroendocrine. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

The native hormone and approved analog drugs should be explained separately.

Human physiology is established, and analog drug evidence exists for specific medicines.

Mechanistic receptor biology is well characterized.

Why this page carries the current tier: Established endogenous biology with clinically important analogs.

The current seed trail for Somatostatin is pulling from 2 databases sources and 1 literature source.

Safety, limits, and regulatory context

Native peptide biology should not be confused with approved analog labels.

The endogenous peptide is biology. Approved analogs should be evaluated as their own drug profiles.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Somatostatin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Somatostatin is CID 16129706. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
16129706
Formula
C76H104N18O19S2
Molecular weight
1637.9
InChIKey
NHXLMOGPVYXJNR-ATOGVRKGSA-N

Matched synonyms include SOMATOSTATIN, Cyclic Somatostatin, 38916-34-6, Somatostatina, Somatostatine, Somatostatin 14, Somatostatin-14, Somatostatinum.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Somatostatin returns 356 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Somatostatin returns 45898 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.